SURF - Surface Oncology, Inc.
| Previous Close | 3.2900 |
| Open | 3.2700 |
| Bid | 0.0000 x 2900 |
| Ask | 0.0000 x 800 |
| Day's Range | 3.0505 - 3.2700 |
| 52 Week Range | 3.0500 - 18.1800 |
| Volume | 56,020 |
| Avg. Volume | 57,790 |
| Market Cap | 87.985M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5770 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.00 |
- GlobeNewswire•13 days ago
Surface Oncology to Participate in 40th Annual Goldman Sachs Global Healthcare Conference
CAMBRIDGE, Mass., June 07, 2019 -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor.
GuruFocus.com•20 days agoAnalysts Recommend These 3 Falling Knives
The following companies can be considered "falling knives" because their share prices have declined more than 59% over the past 52 weeks through May 30. Wall Street is also optimistic about them as it issued recommendation ratings ranging from overweight to buy with average target prices that produce at least 135% stock appreciation within 52 weeks. Warning! GuruFocus has detected 3 Warning Signs with PTE.
- GlobeNewswire•27 days ago
Surface Oncology Presents Preclinical Data Further Supporting Anti-Tumor Mechanism of CD73 and CD39 Programs at Brisbane Immunotherapy 2019
Surface Oncology (SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment (TME), today announced the presentation of updated preclinical findings regarding the anti-tumor effects of increasing inflammation and reducing extracellular adenosine in the TME. The data highlight the mechanisms of targeting CD73 and CD39, which are distinct targets in the adenosine axis and focal points of the Surface Oncology pipeline.
- GlobeNewswire•last month
Surface Oncology to Present at Two Upcoming Healthcare Conferences
CAMBRIDGE, Mass., May 15, 2019 -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor.
- Zacks•last month
Surface Oncology, Inc. (SURF) Reports Q1 Loss, Tops Revenue Estimates
Surface Oncology, Inc. (SURF) delivered earnings and revenue surprises of 65.91% and 477.36%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire•last month
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2019
CAMBRIDGE, Mass., May 09, 2019 -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor.
- GlobeNewswire•2 months ago
Surface Oncology Management to Present at the Solebury Trout Class of 2018 Biotech IPOs Investor Day
CAMBRIDGE, Mass., April 24, 2019 -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor.
- GlobeNewswire•3 months ago
Surface Oncology Announces Appointment of Wendy Dwyer as Chief Business Officer
Surface Oncology (SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the appointment of Wendy Dwyer as chief business officer. Ms. Dwyer will be responsible for Surface’s business development, program and alliance management, and portfolio strategy functions.
- GlobeNewswire•4 months ago
Surface Oncology to Present at the 39th Annual Cowen Healthcare Conference
CAMBRIDGE, Mass., March 04, 2019 -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor.
- Simply Wall St.•4 months ago
Could Surface Oncology, Inc.’s (NASDAQ:SURF) Investor Composition Influence The Stock Price?
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Every investor in Surface Oncology, Inc. (NASDAQ:SURF) should be awareRead More...
- GlobeNewswire•4 months ago
Surface Oncology Retains Worldwide Rights for its First-in-Class Antibody Targeting IL-27, SRF388
Surface Oncology (SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the retention of worldwide rights for its novel antibody, SRF388, targeting IL-27. This program was previously subject to Surface’s collaboration with Novartis. IL-27 is a novel target in immuno-oncology, believed to play a significant and broad role in tumor-related immunosuppression via the regulation of checkpoint protein expression.
- GlobeNewswire•5 months ago
Publication in ImmunoHorizons Highlights the Role of IL-27 in Upregulation of Multiple Checkpoint Proteins
- Expression of IL-27 shown to contribute to upregulation of PD-L1, LAG-3, CTLA-4, and TIGIT - Surface Oncology will submit an IND for SRF388, a first-in-class IL-27 antibody,.
- ACCESSWIRE•5 months ago
Kill the Cancer Stem Cell, Kill the Cancer: How One Biotech is Hitting Cancer at the Cause
TORONTO, ON / ACCESSWIRE / January 10, 2019 / The Wealthy Biotech Trader (or ''WBT''), an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech, pharma, medical device stocks making news and subsequent market moves, would like to update investors on several breakthroughs in cancer therapies hitting the market. Stock investors have soured on biotech companies over the past several months, as demonstrated by the SPDR S&P Biotech ETF (XBI), off 30% since June, and the NYSE Biotechnology Index (NYSE:NBI), which has dropped from 3500 in mid-2018 to just under 3000 at year-end, and a host of their component companies and others in addition. One of those is Propanc Biopharma, Inc. (OTCQB:PPCB), an Australian biotech company with strong management and technology that has the potential to help millions of cancer patients worldwide.
- GlobeNewswire•5 months ago
Surface Oncology Announces Appointment of F. Stephen Hodi, MD to its Scientific Advisory Board
Surface Oncology (SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the appointment of the F. Stephen Hodi, MD to the company’s scientific advisory board (SAB). “Surface Oncology continues to grow and learn as a company and we look to align ourselves with world-class leaders in the fields of oncology and immunology. Steve is a clinical pioneer in the field of cancer immunotherapy.
- GlobeNewswire•6 months ago
Surface Oncology Added to the NASDAQ Biotechnology Index
CAMBRIDGE, Mass., Dec. 21, 2018 -- Surface Oncology (NASDAQ: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor.
- GlobeNewswire•6 months ago
Surface Oncology Resets Portfolio Priorities, Extends Cash Runway Through 2021
“A disciplined approach to both drug development and portfolio prioritization is central to our mission to develop truly innovative immunotherapies to help those affected by cancer,” said Jeff Goater, chief executive officer of Surface Oncology.
- GlobeNewswire•6 months ago
Surface Oncology Promotes Jessica Fees to Senior Vice President, Finance and Business Operations
Surface Oncology (SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced this morning the promotion of Jessica Fees to senior vice president, finance and business operations. She is now responsible for the finance, information technology and facilities functions at Surface. Ms. Fees will also serve as the company’s principal financial and accounting officer, effective December 14, 2018.
- GlobeNewswire•7 months ago
Surface Oncology Announces Upcoming Investor Presentations
Surface Oncology (SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced this morning that it will host presentations at two investor conferences in the month of November. Members of the management team of Surface Oncology will participate in a fireside chat at the 30th Annual Piper Jaffray Healthcare Conference, Tuesday, November 27th, 8:30 a.m. ET at the Lotte Palace Hotel, New York City. Additionally, members of management will participate in the Evercore ISI HealthCONx Conference, Wednesday, November 28, 2:20 p.m. ET at the Boston Harbor Hotel, Boston.
- GlobeNewswire•7 months ago
Surface Oncology Reports Financial Results and Corporate Highlights for Third Quarter 2018
CAMBRIDGE, Mass., Nov. 13, 2018 -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor.
- Benzinga•9 months ago
Surface Oncology Offers 'Robust Pipeline,' Baird Says In Bullish Initiation
In the next few years, Ulz said he anticipates "meaningful upside" stemming from early clinical data on antibodies that inhibit CD47, such as SRF231. The drug has broad utility and a differentiated safety profile, Ulz said. A Novartis AG (NYSE: NVS) partnership should target the adenosine pathway, leading to immunosuppression, Ulz said.
